← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Sep 1, 2026

AYTU BIOPHARMA, INC (AYTU)

Healthcare • NASDAQ

$2.29

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

18.0/100

POOR BUSINESS

AYTU BIOPHARMA, INC (AYTU) scores 18/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full AYTU quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full AYTU valuation analysis · → View full AYTU Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-148.9%)

Debt-to-Equity (Solvency Risk):GOOD (0.36x)

Operating Margin (Operational Efficiency):CRITICAL (-26.8%)

Return on Capital (Capital Efficiency):CRITICAL (-52.4%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

AYTU BIOPHARMA, INC (AYTU) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.29

Market Cap:$24.07M

Valuation Multiples (3)

P/B Ratio:0.68x

P/S Ratio:0.43x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$10.62M

Price Action & Momentum (3)

12-1 Momentum:

+0.9% (35th pctile)

📈 Click to view full AYTU Momentum analysis →

Momentum Percentile:35 / 100

% of 52-Week High:74.7%

B. Profitability Assessment

Return Metrics (5)

ROE:

-148.9%

📊 Click to view full AYTU ROE analysis →

ROA:-28.2%

Roic:

-52.4%

📊 Click to view full AYTU ROIC analysis →

Reinvestment Rate:45.3%

Fundamental Growth Rate (g):-23.7%

Margin Analysis (3)

Operating Margin Ttm:-26.8%

Net Margin Ttm:-60.2%

Ebitda Margin:-16.5%

TTM Performance (3)

Gross Margin Ttm:64.8%

Operating Margin Ttm:-26.8%

Net Margin Ttm:-60.2%

Yield Metrics (2)

Earnings Yield:-$60.92

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

-0.50

📊 Click to view full AYTU Earnings Surprise analysis →

EPS Surprise vs Expected:-401.8%

Latest Earnings Filed:2026-05-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-19.3%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):86.0%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.12x

Quick Ratio:1.00x

Cash Ratio:0.45x

Leverage Analysis (3)

Debt To Equity Ttm:0.36x

Debt-to-Equity Ratio:0.36x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-3.49x

Times Interest Earned:-3.49

Capital Structure (4)

Working Capital:7,354,000.00

Cash And Cash Equivalents:26,715,000.00

Long Term Debt:$11.41M

Net Debt:-$13.45M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $56.60M

Linear Growth: -19.3%

📊 Click to view full AYTU Revenue analysis & methodology →

Cost Of Revenue Ttm:$19.94M

Profitability Breakdown (2)

Gross profit TTM: $36.66M

Linear Growth: -17.2%

📊 Click to view full AYTU Gross Profit analysis & methodology →

-$15.16M

Bottom Line Performance (3)

Net income TTM: -$34.06M

Linear Growth: 86.0%

📊 Click to view full AYTU Net Income analysis & methodology →

Income Before Tax:-$33.67M

Ebitda Ttm:-9,347,000.00

Operating Expenses (5)

Operating Expenses:51,824,000.00

R And D Expense:216,000.00

Sga Expense:18,663,000.00

Income Tax Expense:$447.00K

Interest Expense:2,242,000.00

Expense Ratios (3)

R And D To Revenue Percentage:1.7%

Sga To Revenue Percentage:150.4%

Ebitda Margin:-16.5%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$111.69M

Current Assets:$67.33M

Ppe Net:407,000.00

Goodwill:0.00

Intangible Assets:$42.49M

Liability Structure (4)

Total Liabilities:76,546,000.00

Current Liabilities:59,972,000.00

Long Term Debt:$11.41M

Short Term Debt:$1.86M

Equity & Capital (3)

Equity:$35.14M

Retained Earnings:-$347.77M

Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:24,489,000.00

Inventory:7,460,000.00

Accounts Payable:13,214,000.00

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:148,000.00

C. Cash Flow Analysis

Operating Activities (2)

-$1.94M-$2.17M

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$2.30M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$1.86M

Long Term Debt Repayments:$464.00K

Non-Cash Items (1)

Depreciation Amortization Ttm:5,814,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.55

-$1.45

Earnings Per Share Ttm:-$3.24

Revenue & Cash Per Share (2)

Sales Per Share Ttm:5.38

Operating Cash Flow Per Share:-$0.18

Book Value & Capital (2)

Book Value Per Share:$3.34

Cash Per Share:2.54

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.47x

Working Capital Turnover Ttm:7.70x

Receivables Management (2)

Receivables Turnover Ttm:2.31x

Days Sales Outstanding Ttm:157.93

Inventory Management (2)

Inventory Turnover Ttm:2.67x

Days Inventory Outstanding Ttm:136.58

Payables & Cash Cycle (2)

Days Payable Outstanding:241.93

Cash Conversion Cycle:52.58

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00

Quality Score:30.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:45.3%

Fundamental Growth Rate (g):-23.7%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):-19.3%

Net Income Growth Rate (Linear):86.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-17.2%

Book Value Growth Rate (Linear):-25.3%

C. Company Profile & Context

Corporate Information (6)

Symbol:AYTU

Company Name:AYTU BIOPHARMA, INC

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:low

Volume Category:N/A

Share Structure (3)

Shares Outstanding:10.51M

Shares Outstanding Basic:10.51M

Shares Outstanding Diluted:10.51M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-09-01 10:15:11 UTC

Data Timestamp:2026-08-21T01:08:30.040326